



STUDY PARTICIPATION CARD

KEEP THIS CARD ALWAYS WITH YOU AND IF YOU REQUIRE MEDICAL CARE SHOW THIS CARD

**This patient is participating in a clinical study.
In an emergency situation, please take advice from the Principal Investigator**

Study Details:

D702NC00001 Artemide-Biliary02: Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer

Study

Medicine:

Rilvegostomig (AZD2936)

Patient Enrollment Code:

E							
---	--	--	--	--	--	--	--

Directions for patient:

- At every visit, bring this study participation card.
- Regarding any problems, discomforts, and/ or unwanted or worsening medical conditions that you have had since your last visit, tell your study doctor.
- Regarding all the medicines that you have taken or any changes to your medicines, tell or discuss with your study doctor.
- In case of any change in your contact information (address or telephone number) tell your study doctor/ nurse.

In case of emergency, hospitalization or if medical/surgical intervention is needed, or in case any alterations in your medication are required, or if you are concerned regarding potential interactions with other medications, kindly get in touch with Principal Investigator for additional information.

As required by patients or healthcare professionals, the contact information can be used.

For Emergency Unblinding, the primary line of contact is Principal Investigator.

Contact Name & Phone Number for Principal Investigator:

--

Other Study Site Contact Name & Phone Number:

--

Study Site Name/ Address:

--

Alternate Name & Phone Number for Emergency Unblinding, if unable to get in touch with the Principal Investigator:

--

Secondary line of contact for Emergency Unblinding, only to be used if unable to get in touch with the Principal Investigator.